Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

Table 4 Whole body and selected organ composition at the end of the study.

	Sham Operated (N = 10)	Vehicle Control (N = 12)	GLPL (N = 11)	GLPH (N = 12)	3174L (N = 13)	3174H (N = 7)
Body Wt (g)	511 ± 16	522 ± 17	523 ± 14	518 ± 12	493 ± 10	435 ± 15*
Baseline Body Wt (g)	257 ± 7	272 ± 8	270 ± 7	276 ± 10	258 ± 5	258 ± 5
Fat Mass (g)	58 ± 6	47 ± 6	45 ± 6	51 ± 9	33 ± 3*	26 ± 5*
Lean Mass (g)	35 ± 1	38 ± 1	37 ± 2	35 ± 2	38 ± 2	34 ± 1
Fluid Mass (g)	323 ± 12	343 ± 9	329 ± 14	331 ± 15	332 ± 11	305 ± 9*
LV (g)	1.07 ± 0.06*	1.36 ± 0.10	1.26 ± 0.05	1.13 ± 0.03*	1.13 ± 0.05*	1.06 ± 0.04*
RV (g)	0.22 ± 0.01*	0.28 ± 0.02	0.22 ± 0.01*	0.23 ± 0.01*	0.24 ± 0.01*	0.20 ± 0.02*
Lung (g)	1.53 ± 0.05*	2.45 ± 0.05	1.94 ± 0.35	1.66 ± 0.13*	1.48 ± 0.03*	1.51 ± 0.07*
LV Wt/Body Wt (%)	0.21 ± 0.01*	0.26 ± 0.01	0.24 ± 0.01	0.22 ± 0.01*	0.23 ± 0.01*	0.24 ± 0.01
RV Wt/Body Wt (%)	0.04 ± 0.002*	0.05 ± 0.01	0.04 ± 0.002*	0.04 ± 0.002*	0.05 ± 0.002	0.05 ± 0.002
Lung Wt/Body Wt (%)	0.30 ± 0.01*	0.48 ± 0.10	0.37 ± 0.07	0.32 ± 0.02*	0.30 ± 0.01*	0.33 ± 0.01*
Infarct Size (%)	0 ± 0	33 ± 4	30 ± 2	29 ± 2	31 ± 3	31 ± 6

Mean ± SEM. *P < 0.05 versus vehicle-treated group. Wt, weight; LV, left ventricle; RV, right ventricle.

ISSN: 1475-2840